Week of April 26th, 2021 | Vol. 10, Issue 17
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Tribute
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in Canada

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
Thermo Fisher Scientific has acquired clinical research services provider PPD for $17.4 billion.
PPD provides a broad range of clinical research and laboratory services to enable customers to accelerate innovation and increase drug development productivity. A leader in the growing $50 billion clinical research services industry, PPD has more than 26,000 colleagues operating in nearly 50 countries. In 2020, the company generated revenue of $4.7 billion. Upon close of the transaction, PPD will become part of Thermo Fisher’s Laboratory Products and Services Segment.

An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
14 transactions totaling $266 million
Supplies, Equipment & Services
26 transactions totaling $1,974 million
Healthcare IT & Managed Care
3 transactions totaling $153 million
Healthcare Facilities & Distributors
12 transactions totaling $319 million
Pharma & Biotech
34 transactions totaling $1,074 million
Supplies, Equipment & Services
34 transactions totaling $515 million
Healthcare IT & Managed Care
12 transactions totaling $175 million
Healthcare Facilities & Distributors
3 transactions totaling $68 million
Pharma & Biotech
19 transactions totaling $2,431 million
Supplies, Equipment & Services
10 transactions totaling $2,817 million
Healthcare IT & Managed Care
1 transaction totaling $25 million
Healthcare Facilities & Distributors
1 transaction
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
April 23, 2021 - Fierce Pharma
Switzerland’s Lonza has been hard at work ramping up its manufacturing capabilities for a handful of COVID-19 products, including a decade-long deal to produce Moderna’s mRNA vaccine. Now, the CDMO giant is adding oncology to its to-do list and will build a brand new small molecule facility with the help of an undisclosed “biopharmaceutical partner.” 

April 23, 2021 - Fierce Healthcare
Under the terms of the agreement, the purchase price of up to $450 million will consist of $40 million in cash, $340 million in Accolade common stock, and up to an additional $70 million of value payable upon the achievement of defined revenue milestones following the closing, the company said in a press release issued Friday.

April 23, 2021 - Fierce Pharma
With COVID-19 boosting the company's profile in a big way, Regeneron is returning to a long-running expansion with plans to inject some fresh cash into the project. 
Regeneron has designs on a $480 million manufacturing upgrade at its home base in Tarrytown, New York, Westfair Online reports, citing company talks with Westchester County's Industrial Development Agency (IDA).

April 19, 2021 - Contract Pharma
National Resilience, Inc., a company that says it is building a biopharmaceutical manufacturing ecosystem, has acquired Ology Bioservices, a privately held company that also specializes in biologic drug substance manufacturing from early stage through commercial products.
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.